BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29145707)

  • 1. Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism.
    Lood Y; Aardal-Eriksson E; Webe C; Ahlner J; Ekman B; Wahlberg J
    Andrology; 2018 Jan; 6(1):86-93. PubMed ID: 29145707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary testosterone measurement by liquid chromatography tandem mass spectrometry in adult males and females.
    Keevil BG; MacDonald P; Macdowall W; Lee DM; Wu FC;
    Ann Clin Biochem; 2014 May; 51(Pt 3):368-78. PubMed ID: 24194586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary testosterone: a reliable approach to the diagnosis of male hypogonadism.
    Arregger AL; Contreras LN; Tumilasci OR; Aquilano DR; Cardoso EM
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):656-62. PubMed ID: 17953627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate.
    Tschöp M; Behre HM; Nieschlag E; Dressendörfer RA; Strasburger CJ
    Clin Chem Lab Med; 1998 Apr; 36(4):223-30. PubMed ID: 9638347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical evaluation of salivary testosterone as a method for the assessment of serum testosterone.
    Fiers T; Delanghe J; T'Sjoen G; Van Caenegem E; Wierckx K; Kaufman JM
    Steroids; 2014 Aug; 86():5-9. PubMed ID: 24793565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference ranges for serum and salivary testosterone in young men of Mediterranean region.
    González-Sánchez V; Moreno-Pérez O; García de Guadiana L; Sánchez-Pellicer P; Alfayate R; Mauri M; Sánchez-Payá J; Picó A
    Endocrinol Nutr; 2015 Jan; 62(1):4-10. PubMed ID: 25444977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
    Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validating the salivary testosterone and cortisol concentration measures in response to short high-intensity exercise.
    Crewther BT; Lowe TE; Ingram J; Weatherby RP
    J Sports Med Phys Fitness; 2010 Mar; 50(1):85-92. PubMed ID: 20308978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men.
    Schürmeyer T; Wickings EJ; Freischem CW; Nieschlag E
    Acta Endocrinol (Copenh); 1983 Mar; 102(3):456-62. PubMed ID: 6402875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which androgen replacement therapy for women?
    Buckler HM; Robertson WR; Wu FC
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3920-4. PubMed ID: 9814469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.